Mean (SE) % fall in FEV1 from pre-challenge value for first and last doses of randomised treatments after methacholine challenge before salbutamol, salbutamol recovery over 30 minutes (%.min), and % fall from pre-challenge value 30 minutes after salbutamol
| Genotype | BUD + FM | FP + SM | |||||
|---|---|---|---|---|---|---|---|
| First dose | Last dose | 95% CI | First dose | Last dose | 95% CI | ||
| BUD = budesonide; FM = formoterol, FP = fluticasone propionate; SM = salmeterol. | |||||||
| *p<0.05 first dose v last dose of each randomised treatment. | |||||||
| There were no significant differences in either genotype or treatment group for % fall in FEV1 from the pre-challenge value after methacholine challenge pre salbutamol. | |||||||
| % fall from pre-challenge FEV1 after methacholine challenge pre salbutamol | |||||||
| Arg-16 | 25 (2) | 29 (2) | (−2.3 to 9.7) | 26 (2) | 27 (1) | (−5.7 to 6.9) | |
| Gly-16 | 25 (3) | 25 (2) | (−5.7 to 5.9) | 24 (3) | 22 (4) | (−8.7 to 5.9) | |
| 95% CI | (−7 to 7) | (−3 to 10) | (−5 to 11) | (−4 to 14) | |||
| Salbutamol recovery | |||||||
| Arg-16 | 386 (48) | 591 (60)* | (97−314) | 363 (53) | 529 (43)* | (40 to 292) | |
| Gly-16 | 352 (56) | 491 (34)* | (9−269) | 289 (62) | 466 (68)* | (36 to 319) | |
| 95% CI | (−122 to 189) | (−51 to 250) | (−97 to 246) | (−107 to 233) | |||
| % fall from pre-challenge FEV1 30 minutes after salbutamol | |||||||
| Arg-16 | 6 (2) | 13 (2)* | (4 to 10) | 5 (2) | 12 (2)* | (3 to 11) | |
| Gly-16 | 6 (2) | 10 (2)* | (1 to 9) | 2 (2) | 10 (2)* | (2 to 14) | |
| 95% CI | (−5 to 7) | (−3 to 9) | (−3 to 10) | (−4 to 9) | |||